Hepatitis B
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: Hepatitis B
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 Liver Meeting, the annual conference of the American Association for the Study of Liver Diseases, AASLD), October 20-24, 2017, in Washington, DC.
Hepatitis C
- More Work and Lower Drug Prices Needed to Eliminate Hepatitis C Worldwide
- Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV
- Curing Hepatitis C Leads to Improved Quality of Life
- Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis
- Curing Hepatitis C with DAAs Reduces Liver Cancer Risk
- HCV Infections Are Rising Among HIV+ Gay Men In San Diego
- Model Shows Hepatitis C Treatment is Cost-Effective in Japan
- Hepatitis C Testing Linked to Reduced Opioid Use
Hepatitis B
- TAF for Hepatitis B Improves Kidney Function and Bone Loss
- REP 2139 Combination Therapy Leads to Functional Control of Hepatitis B Virus
- Immune Modulator Inarigivir Looks Promising for People with Hepatitis B
- RNA Interference Therapy Lowers Viral Biomarker in People with Hepatitis B
- Treatment that Interferes with Viral Assembly Shows Promise for Hepatitis B
- Daily Aspirin Linked to Lower Liver Cancer Risk for Hepatitis B Patients
Fatty Liver Disease
- Experimental NASH Therapy Improves Liver Fat and Fibrosis
-
Women with Fatty Liver Disease at Higher Risk for Heart Disease
Liver Cancer
- Nivolumab Improves Outcomes in Liver Cancer Study
- Daily Aspirin Linked to Lower Liver Cancer Risk for Hepatitis B Patients
- Curing Hepatitis C with DAAs Reduces Liver Cancer Risk
11/30/17